Search

Your search keyword '"Terrat, Céline"' showing total 14 results
Start Over Author "Terrat, Céline"
14 results on '"Terrat, Céline"'

4. Synthetic self-assembling ADDomer platform for highly efficient vaccination by genetically encoded multiepitope display

Author

Vragniau, Charles, primary, Bufton, Joshua C., additional, Garzoni, Frédéric, additional, Stermann, Emilie, additional, Rabi, Fruzsina, additional, Terrat, Céline, additional, Guidetti, Mélanie, additional, Josserand, Véronique, additional, Williams, Matt, additional, Woods, Christopher J., additional, Viedma, Gerardo, additional, Bates, Phil, additional, Verrier, Bernard, additional, Chaperot, Laurence, additional, Schaffitzel, Christiane, additional, Berger, Imre, additional, and Fender, Pascal, additional

Published
2019
Full Text
View/download PDF

5. Exploiting Natural Cross-reactivity between Human Immunodeficiency Virus (HIV)-1 p17 Protein and Anti-gp41 2F5 Antibody to Induce HIV-1 Neutralizing Responses In Vivo

Author

Verrier, Bernard, Paul, Stéphane, Terrat, Céline, Bastide, Liza, Ensinas, Agathe, Phelip, Capucine, Chanut, Blandine, Bulens-Grassigny, Laura, Jospin, Fabienne, Guillon, Christophe, Institut de biologie et chimie des protéines [Lyon] (IBCP), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Groupe d'Immunité des Muqueuses et Agents Pathogènes, Université de Lyon, Laboratoire de Biologie Tissulaire et d'ingénierie Thérapeutique UMR 5305 (LBTI), Microbiologie moléculaire et biochimie structurale / Molecular Microbiology and Structural Biochemistry (MMSB), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Groupe Immunité des Muqueuses et Agents Pathogènes (GIMAP), Université Jean Monnet [Saint-Étienne] (UJM), Department of Virology, Erasmus Medical Centre, Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), and Université de Lyon-Université de Lyon

Subjects
cross-reactivity, viruses, Immunology, virus diseases, p17, gp41, human immunodeficiency virus-1, [SDV.IMM.IA]Life Sciences [q-bio]/Immunology/Adaptive immunology, immune system diseases, antigen engineering, Immunology and Allergy, neutralizing antibodies, [SDV.IMM.VAC]Life Sciences [q-bio]/Immunology/Vaccinology, ComputingMilieux_MISCELLANEOUS
Abstract

Anti-p17 antibodies are able to neutralize human immunodeficiency virus (HIV) entry in a mouse model. In this study, we identified a region of sequence similarity between the epitopes of anti-p17 neutralizing antibodies and anti-gp41 neutralizing 2F5 antibody and verified cross-reactivity between p17 and 2F5 in vitro. The p17 sequence was modified to increase sequence identity between the p17 and 2F5 epitopes, which resulted in enhanced cross-reactivity in vitro. Immunogenicity of wild-type and modified p17 was characterized in a rabbit model. Both wild-type and mutated p17 induced anti-gp41 responses in rabbits; sera from these animals reacted with gp41 from different HIV clades. Moreover, introduction of the 2F5 sequence in p17 resulted in induction of antibodies with partially neutralizing activity. Based upon these data, we suggest that the natural cross-reactivity between HIV-1 p17 protein and 2F5 antibody can be exploited to induce antibodies with neutralizing activity in an animal model.

Published
2017

13. Short Communication: Retrospective Study to Time the Introduction of HIV Type 1 Non-B Subtypes in Lyon, France, Using env Genes Obtained from Primary Infection Samples

Author

Vachot, Laurence, Ataman-Önal, Yasemin, Terrat, Céline, Durand, Pierre-Yves, Ponceau, Bénédicte, Biron, François, and Verrier, Bernard

Abstract

Using blood samples from primary HIV-1 infection (PHI) patients obtained in Lyon, France, we characterized the newly transmitted HIV-1 variants in this area during the 1992–1996 period. As PHI samples allowed the precise timing of the transmission event, we were able to date the introduction of non-B subtypes or recombinant forms of the virus in Lyon. Genomic DNA from 18 HIV-1-positive patients at primary infection was used to amplify the full-length env gene by nested PCR; after cloning, the gene was sequenced for subsequent phylogenetic analysis. Several non-B subtypes and recombinant forms of HIV-1 were identified among the 18 patients studied (1 subtype F1, 1 CRF01-AE, 2 subtype G and 2 CRF02–AG). We also found a new J/K recombinant form transmitted in 1995 and never described until now. The introduction of CRF02-AG in Lyon, France, occurred prior to 1992 and six transmission events including non-B subtypes were documented in the following 4 years. Heterosexual contacts appeared as the main introduction pathway for non-B subtypes or recombinant forms. Nevertheless, as transmission of these viruses occurred not only during travel to endemic regions, but also in France or Germany, we conclude that non-B strains entered Europe before the studied period. This retrospective study showed that even if subtype B remained prevalent in the spreading HIV-1 infection in Lyon between 1992 and 1996, non-B subtypes and circulating recombinant forms represented a significantly growing part.

Published
2004
Full Text
View/download PDF

14. Exploiting Natural Cross-reactivity between Human Immunodeficiency Virus (HIV)-1 p17 Protein and Anti-gp41 2F5 Antibody to Induce HIV-1 Neutralizing Responses In Vivo .

Author

Verrier B, Paul S, Terrat C, Bastide L, Ensinas A, Phelip C, Chanut B, Bulens-Grassigny L, Jospin F, and Guillon C

Abstract

Anti-p17 antibodies are able to neutralize human immunodeficiency virus (HIV) entry in a mouse model. In this study, we identified a region of sequence similarity between the epitopes of anti-p17 neutralizing antibodies and anti-gp41 neutralizing 2F5 antibody and verified cross-reactivity between p17 and 2F5 in vitro . The p17 sequence was modified to increase sequence identity between the p17 and 2F5 epitopes, which resulted in enhanced cross-reactivity in vitro . Immunogenicity of wild-type and modified p17 was characterized in a rabbit model. Both wild-type and mutated p17 induced anti-gp41 responses in rabbits; sera from these animals reacted with gp41 from different HIV clades. Moreover, introduction of the 2F5 sequence in p17 resulted in induction of antibodies with partially neutralizing activity. Based upon these data, we suggest that the natural cross-reactivity between HIV-1 p17 protein and 2F5 antibody can be exploited to induce antibodies with neutralizing activity in an animal model.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results